💊 Medical & Pharmaceutical Updated August 2026

Hair Relaxer and Hair Product Lawsuits

Hair relaxer litigation alleges that chemical straightening products containing endocrine disrupting compounds increased the risk of uterine and ovarian cancer.

Category

Medical & Pharmaceutical

Coverage

Ongoing

Last Updated

August 2026

Content Type

Legal Analysis

What These Claims Allege

Chemical hair straighteners work by breaking and reforming the protein bonds in hair. The litigation concerns formulations alleged to contain phthalates, parabens and other endocrine disrupting compounds, and to release formaldehyde during heat application.

The claims gained momentum after published research reported an association between frequent long-term use and uterine cancer. Because these products were marketed heavily to Black women, the exposed population is concentrated and the claims have a distinct demographic profile.

These are product liability claims on design defect and failure-to-warn theories, with additional allegations concerning ingredient disclosure. Cosmetic labelling rules historically permitted considerable latitude, including grouping constituents under general terms.

Causation is the principal battleground. The claimants rely on epidemiological association together with a biological mechanism through endocrine disruption. Defendants dispute the strength of that association and point to other risk factors.

Cases Covered in This Section

This section tracks 5 active or resolved matters. Each has its own detailed page covering the allegations, who may qualify, and what the process involves.

Who May Have a Claim

Claims generally involve regular use of chemical relaxers or straighteners over a period of years, followed by a diagnosis of uterine cancer, uterine sarcoma, endometrial cancer or ovarian cancer.

Evidence of use matters: salon records, purchase history, brand identification and consistent testimony about frequency and duration. Because use often began in childhood, the exposure period in these claims is frequently long.

Where the Litigation Stands

Federal claims have been consolidated in multidistrict litigation, with the early phases focused on case management, product identification and the expert evidence on general causation.

General causation rulings are the pivotal stage in litigation of this kind. Whether the plaintiffs epidemiological evidence is admitted will substantially determine how the claims proceed.

Free Legal Evaluation

Do You Qualify to File a Claim?

Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.

Hair Relaxer Chemical Straightener Uterine Cancer Endocrine Disruptors

Hair Relaxer and Hair Product Lawsuits: Frequently Asked Questions

Answers to the most common questions about this case and your legal options.

What cancers are associated with hair relaxers?

The claims focus on uterine cancer, endometrial cancer, uterine sarcoma and ovarian cancer. Uterine cancer has the most prominent supporting research, and breast cancer claims have also been raised though with a more contested evidence base.

How much use is needed for a claim?

There is no fixed threshold, but claims generally involve regular use over a period of years, often measured in multiple applications per year over a decade or more. Frequency and duration are typically central to both eligibility and value.

Do I need to remember the brands I used?

Product identification strengthens a claim considerably, since it establishes which manufacturers are defendants. Salon records, purchase history, photographs and consistent testimony can all help establish which products were used and when.

Why were these products marketed to Black women?

Chemical straighteners were marketed predominantly to Black women over several decades, which is why the exposed population is concentrated. That marketing history is itself part of the factual record in the litigation.

What stage is this litigation at?

Federal cases are consolidated in multidistrict litigation and remain in the pretrial phase, with general causation expert evidence the key issue. No global settlement has been reached, and rulings on the scientific evidence will shape what follows.

LawsuitWatch Legal Research Team

Medical & Pharmaceutical Litigation Desk

The LawsuitWatch Legal Research Team monitors federal court PACER filings, MDL docket activity, regulatory enforcement actions, and legal settlements to deliver accurate, timely coverage of litigation affecting American consumers. Content is reviewed for factual accuracy before publication and updated as cases develop. Last reviewed: August 2026.